Merck’s Keytruda Gets EU Approval for Treatment of Triple-Negative Breast Cancer.
The European Commission has cleared Keytruda (Pembrolizumab) in combination with chemotherapy as a first-line treatment for locally recurrent, unresectable or metastatic TNBC…